Primobolan Inj (Methenolon Enantat) Core Labs 10ml

Description

Methenolone Enanthate

Strength: 100 mg/ml

Molecular Formula: C27H42O3

Molecular Weight: 414.62058 g/mol

Active Ingredient: Methenolone enanthate

CAS number: 303-42-4 Dosage Form: Injectable, oil base sterile solution

Route: Injection

Market Status: Prescription

Company: Hilma Biocare

DESCRIPTION

Methenolone Enanthate 100 is a dihydrotestosterone derived anabolic steroid. Methenolone

Enanthate 100 contains methenolone enanthate, a long- acting methenolone ester

producing a rapid onset of serum methenolone with a continued duration of action of 5 to 7

days after IM injection. Methenolone Enanthate 100 is moderately anabolic with limited

androgenic properties. Methenolone cannot aromatize to estrogen, reducing estrogenic side

effects, and has a favorable safety profile among anabolic agents.

CLINICAL PHARMACOLOGY

Anabolic steroids are synthetic derivatives of testosterone. Certain clinical effects and

adverse reactions demonstrate the androgenic properties of these drugs. Complete

dissociation of anabolic and androgenic effects has not been achieved. The actions of

anabolic steroids are thus similar to those of male sex hormones. Anabolic steroids suppress

the gonadotropic functions of the pituitary and may exert a direct effect upon the testes.

During exogenous administration of anabolic androgens, endogenous testosterone release

is inhibited through inhibition of pituitary luteinizing hormone (LH). At large doses,

spermatogenesis may be suppressed through feedback inhibition of pituitary folliclestimulating hormone (FSH). Methenolone is a dihydrotestosterone derivative which cannot

be aromatized to estrogen and which acts upon the androgen receptor stimulating anabolism

through increased nitrogen retention and protein synthesis in muscle tissue. Methenolone

enanthate in a single dose pharmacokinetic study has demonstrated a mean elimination

half-life of 6 days.

INDICATIONS

As an alternate or adjunctive therapy in patients for the promotion of weight gain following

weight loss and/or muscular atrophy associated with extensive surgery, chronic infections,

long term hospitalization, or severe trauma. To compensate for protein catabolism

consequent to corticosteroid therapy.

DOSAGE AND ADMINISTRATION

Adult male: 100 – 200 mg injected IM every 3 – 5 days for a duration of 8 to 12 weeks.

ADVERSE REACTIONS

Male: Gynecomastia, increased frequency of erections, azoospermia, priapism,

oligospermia, prostatic hypertrophy.increased risk of prostate carcinoma.

Skin and Appendages: Hirsutism, pattern baldness and acne, gynecomastia,

Fluid/Electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and

inorganic phosphates.

Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests; rarely,

hepatocellular neoplasms, peliosis hepatis, hepatic adenomas, and cholestatic hepatitis.

Hematologic: Suppression of clotting factors II, V, VII, & X; bleeding in patients on anticoagulant therapy.

Nervous System: Increased or decreased libido, headache, anxiety, depression, and

generalized paresthesia.

Metabolic: Reduced glucose tolerance and inhibition of gonadotropin secretion.

Other: Serum lipid changes, hypercalcaemia, hypertension, oedema, and potentiation of

sleep apnea.

CONTRAINDICATIONS

Patients with diagnosed or suspected carcinoma of the prostate, breast, or testis. Patients

with diagnosed or suspected female breast carcinoma with hypercalcemia as androgenic

agents may increase osteolytic bone resorption. Women who are pregnant or may become

pregnant because of possible masculinization of the fetus. Patients with nephrosis or the

nephrotic phase of nephritis. Patients with hypercalcemia. Hypersensitivity to this product or

any of its ingredients. Patients with pre-existing cardiac, renal, and/or hepatic disease.

Discontinue treatment upon signs of jaundicing or hepatotoxicity.

PRECAUTIONS

Because androgens may alter serum cholesterol concentration, caution should be used

when administering these drugs to patients with a history of myocardial infarction or coronary

artery disease. Patients on oral anticoagulant therapy require close monitoring especially

when androgens are started or stopped.

Diabetics: androgens may alter the metabolism of oral hypoglycemic agents or may change

insulin sensitivity in patients with diabetes mellitus which may require adjustment of dosage

of insulin and other hypoglycemic drugs.